Product
GPC2 CAR T cells
1 clinical trial
2 indications
Indication
NeuroblastomaIndication
High-risk NeuroblastomaClinical trial
Phase 1 Trial of GPC2-Directed Chimeric Antigen Receptor Autologous T Cells (GPC2 CAR T) for Relapsed or Refractory NeuroblastomaStatus: Recruiting, Estimated PCD: 2025-01-30